OXYCOMPLEX NS

Oxytetracycline 100mg/ml as Oxytetracycline Hydrochloride
Flunixin 20mg/ml as Flunixin Meglumine

DATA SHEET

INDICATIONS

Oxycomplex NS Solution for Injection is licensed for the control and treatment of infectious diseases of cattle caused by or associated with organisms sensitive to oxytetracycline, where concurrent analgesic, anti-inflammatory, anti-endotoxic or antipyretic therapy is desired.

The product is especially indicated for the treatment of respiratory disease (particularly that associated with *Pasteurella* infection) and acute mastitis (in conjunction with appropriate intramammary therapy).

BENEFITS

- For intravenous & deep intramuscular use
- A useful combination product with an antibiotic and an anti inflammatory agent
- Broad spectrum activity against Gram-negative and Gram-positive bacteria
- Rapid response
- For treatment of pneumonia, acute mastitis and disease associated with organisms sensitive to oxytetracycline

LIST No	UNIT PACKAGE	CASE SIZE
1OXY005	100ml	12

See reverse for Administration & Dosage

Oxycomplex NS
Solution for Injection

Oxytetracycline 100mg/ml as Oxytetracycline Hydrochloirde
Flunixin 20mg/ml as Flunixin Meglumine

PRESENTATION
An aqueous solution for injection. Each ml contains 100mg Oxyteracycline (as oxytetracycline hydrochloride) and 20mg Flunixin (as flunixin meglumine)

TARGET SPECIES
Cattle.

INDICATIONS FOR USE
For the control and treatment of infectious diseases of cattle caused by or associated with organisms sensitive to oxytetracycline, where concurrent analgesic, anti-inflammatory, antiendotoxic or antipyretic therapy is desired.
The product is especially indicated for the treatment of respiratory disease (particularly that associated with *Pasteurella* infection) and acute mastitis.

CONTRAINDICATIONS
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Not suitable for donkeys or horses.

SPECIAL WARNINGS FOR EACH TARGET SPECIES
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk.
If such use cannot be avoided animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a potential risk of renal toxicity. It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.
Concurrent administration of methoxyflurane anaesthesia or other potentially nephrotoxic drugs should be avoided.

SPECIAL PRECAUTIONS FOR USE
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

ADVERSE REACTIONS
Prolonged use of NSAIDs, including flunixin, may predispose or lead to gastrointestinal ulceration.

USE DURING PREGNANCY, LACTATION OR LAY
Safe for use in pregnant and lactating animals.
The use of tetracyclines during the period of tooth development, including late pregnancy, may lead to tooth discolouration.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONS
The product may potentiate the effects of Warfarin and related drugs. Because of their common mode of action, flunixin may potentiate and be potentiated by other NSAIDs which act by interfering with prostaglandin synthesis.
Where other products are to administered concurrently, drug capability should be carefully monitored.
Corticosteroids should bot be used concurrently with this product.

AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
By intravenous or deep intramuscular injection at a rate of 1 ml per 10 kg bodyweight (equivalent to 10 mg oxytetracycline and 2 mg flunixin per kg bodyweight) daily for up to 5 days.
Do not inject more than 20 ml intramuscularly at a single site. Where the dose exceeds 20 ml it should be divided between two or more sites, as appropriate.

OVERDOSE
Overdosing by intramuscular injection may give rise to swellings at the site of injection. Treatment should be symptomatic.

WITHDRAWAL PERIODS
Meat: Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 28 days following the last treatment.
Milk: Milk for human consumption must not be taken during treatment. Milk for human consumption may be taken from cows only after 10 milkings (5 days) following the last treatment.
Where cows are milked twice daily milk may be taken for human consumption from the 11th milking following the last treatment.

SHELF LIFE
(a) Shelf-Life – of the veterinary medicinal product as packaged for sale: 2 years
(b) Shelf-Life – after first opening the immediate packaging: 28 days

SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 25°C. Protect from light.

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED MEDICINAL PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

MARKETING AUTHORISATION HOLDER
Bimeda Animal Health Limited
2, 3 & 4 Airton Close, Airton Road
Tallaght, Dublin 24, Ireland
Tel: +353 (0) 1 466 7900

MARKETING AUTHORISATION NUMBER
VPA 22033/042/001

LEGAL CATEGORY
POM

PACKAGE QUANTITIES
100ML MULTIDOSE VIALS

A full product SPC is available on request from Bimeda or alternatively can be found on the HPRA website.

TAKE TIME  OBSERVE LABEL DIRECTIONS

www.bimeda.ie

Bimeda data sheet created: February 2021